๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase I Trial of Paclitaxel, Carboplatin, and Methotrexate With Granulocyte Colony-Stimulating Factor and Leucovorin in Advanced Transitional Cell Carcinoma

โœ Scribed by Edelman, M.H.; Meyers, F.J.; Houston, J.; Lauder, I.

Book ID
122376882
Publisher
Lippincott Williams and Wilkins
Year
1999
Tongue
English
Weight
211 KB
Volume
161
Category
Article
ISSN
0022-5347

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase I trial of paclitaxel, carboplatin
Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer
โœ John D. Hainsworth; Howard A. Burris III; Lisa H. Morrissey; F. Anthony Greco ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 72 KB ๐Ÿ‘ 3 views

## Background: Topotecan is a new antineoplastic agent with a broad spectrum of activity. the purpose of this phase i trial was to define the maximum tolerated dose of topotecan when added to the widely used combination of paclitaxel and carboplatin. ## Methods: Patients with advanced cancer that

Phase I/II study of carboplatin and oral
Phase I/II study of carboplatin and oral etoposide with granulocyte-colony stimulating factor in advanced nonsmall cell lung cancer
โœ Giuseppe Frasci; Giovanni Persico; Giuseppe Perillo; Giuseppe Comella; Pasquale ๐Ÿ“‚ Article ๐Ÿ“… 1995 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 665 KB

Background. A combination of carboplatin (CBDCA) and oral etoposide is better tolerated than, and as effective as, more aggressive chemotherapy regimens in patients with advanced nonsmall cell lung cancer (NSCLC). A Phase 1/11 study was conducted to determine whether the addition of the granulocyte-

A Phase I trial of intravenous melphalan
A Phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma
โœ David M. Gershenson; Mitchell Morris; Thomas W. Burke; Charles Levenback; Judith ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 96 KB ๐Ÿ‘ 2 views

The primary purpose of this study was to establish the maximum tolerated dose (MTD) of intravenous melphalan in combination with paclitaxel and cisplatin plus granulocyte-colony stimulating factor (G-CSF) in patients with suboptimal advanced epithelial ovarian carcinoma or primary peritoneal carcino